September 16, 2020

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

A new discovery in pluripotent stem cells and induced regenerative medicine

In vitro culture of induced trophoblast stem cells (pink) wrapping clusters of naive induced pluripotent stem cells (cyan). Credit: Xiaodong Liu, Jia Tan and Monika Mohenska
× close
In vitro culture of induced trophoblast stem cells (pink) wrapping clusters of naive induced pluripotent stem cells (cyan). Credit: Xiaodong Liu, Jia Tan and Monika Mohenska

An international collaboration involving Duke-NUS Medical School and Monash University researchers has made an unexpected world-first stem cell discovery that may lead to new treatments for placenta complications during pregnancy.

While it is widely known that adult skin cells can be reprogrammed into cells similar to that can then be used to develop tissue from human organs—known as induced (iPSCs) – the same process could not create tissue.

iPSCs opened up the potential for personalized cell therapies and new opportunities for , safe drug testing and toxicity assessments, however little was known about exactly how they were made.

An international team led by ARC Future Fellow Professor Jose Polo from Monash University's Biomedicine Discovery Institute and the Australian Research Medicine Institute, together with Assistant Professor Owen Rackham from Duke-NUS in Singapore, examined the molecular changes the adult skin cells went through to become iPSCs. It was during the study of this process that they discovered a new way to create induced trophoblast stem cells (iTSCs) that can be used to make placenta cells.

This exciting discovery, also involving the expertise of three first authors, Dr. Xiaodong Liu, Dr. John Ouyang and Dr. Fernando Rossello, will enable further research into new treatments for placenta complications and the measurement of drug toxicity to placenta , which has implications during pregnancy.

"This is really important because iPSCs cannot give rise to placenta, thus all the advances in disease modeling and cell therapy that iPSCs have brought about did not translate to the placenta," Prof Polo said.

"When I started my Ph.D. five years ago, our goal was to understand the nuts and bolts of how iPSCs are made. However, along the way, we also discovered how to make iTSCs," said Dr. Liu.

"This discovery will provide the capacity to model human placenta in vitro and enable a pathway to future cell therapies," said Dr. Ouyang.

"This study demonstrates how by successfully combining both cutting edge experimental and computational tools, basic science leads to unexpected discoveries that can be transformative," Asst Prof Rackham said.

Professors Polo and Rackham said many other groups from Australian and international universities contributed to the study over the years, making it a truly international endeavor.

More information: Reprogramming roadmap reveals route to human induced trophoblast stem cells. Nature (2020). DOI: 10.1038/s41586-020-2734-6, www.nature.com/articles/s41586-020-2734-6

Journal information: Nature

Load comments (0)